Posted on Saturday, December 15th, 2018 by MarketBeat StaffDid you know the S&P 500 as we know it today does not look anything close to what it looked like 30 years ago? In 1987, IBM, Exxon, GE, Shell, AT&T, Merck, Du Pont, Philip Morris, Ford and GM had the largest market caps on the S&P 500. ExxonMobil is the only company on that list to remain in the top 10 in 2017. Even just 15 years ago, companies like Radio Shack, AOL, Yahoo and Blockbuster were an important part of the S&P 500. Now, these companies no longer exist as public companies.
As the years go by, some companies lose their luster and others rise to the top of the markets. We've already seen this in the last few decades with tech companies surpassing industrial and energy companies that once dominated the S&P 500. It's hard to know what the next mega trend will be that will knock Apple, Google and Amazon off the top rankings of the S&P 500, but we do know that companies won't stay on the S&P 500 forever.
We've identified 20 companies that are past their prime. They aren't at risk of a near-term delisting from the S&P 500, but they are showing negative earnings growth for the next several years. If you own any of these stocks, consider selling them now before they become the next Yahoo, Radio Shack, Blockbuster, AOL and are sold off for a fraction of their former value.
#1 - Sailpoint Technologies (NYSE:SAIL)
Trailing Twelve Months EPS: $0.04
2018 EPS Estimate: $0.04
2019 EPS Estimate: ($0.10)
Stock Price: $24.32
P/E Ratio: 608.0
Consensus Rating: Buy
Ratings Breakdown: 9 Buy Ratings, 3 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $31.4167 (29.2% Upside)
SailPoint Technologies Holdings, Inc. designs, develops, and markets identity governance software solutions in North America, Europe, and the Asia Pacific. The company offers on-premises software and cloud-based solutions, which empower organizations to govern the digital identities of employees, contractors, business partners, and other users, as well as manage their constantly changing access rights to enterprise applications and data across hybrid IT environments. Its solutions include IdentityIQ, an on-premises identity governance solution; IdentityNow, a cloud-based multi-tenant governance suite; SecurityIQ, an on-premises identity governance for files solution that secures access to data stored in file servers, collaboration portals, mailboxes, and cloud storage systems; and IdentityAI, a cloud-based identity analytics solution for organizations to detect potential threats before they turn into security breaches. The company sells its products and solutions to commercial enterprises, educational institutions, and governments directly, as well as through resellers. SailPoint Technologies Holdings, Inc. was founded in 2004 and is headquartered in Austin, Texas.
#2 - Pegasystems (NASDAQ:PEGA)
Trailing Twelve Months EPS: $0.22
2018 EPS Estimate: ($0.08)
2019 EPS Estimate: ($0.30)
Stock Price: $49.09
P/E Ratio: 223.1
Dividend Yield: 0.24 %
Consensus Rating: Buy
Ratings Breakdown: 4 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $71.75 (46.2% Upside)
Pegasystems Inc. develops, markets, licenses, and supports software applications for marketing, sales automation, customer service, and operations in the United States and internationally. It provides Pega Platform, an application development product for clients. The company offers customer engagement applications, including Pega Marketing that enable enterprises to enhance customer acquisition and experiences across inbound, outbound, and paid media channels; Pega sales automation to automate and manage the sales process; and Pega customer service to anticipate customer needs, connect customers, the right people and systems, and automate customer interactions to evolve the customer service experience and to allow enterprises to deliver interactions across channels and enhance employee productivity. It also provides digital process automation products, such as industry-specific software applications that include real-time, omni-channel AI; end-to-end robotic automation; journey-centric rapid delivery; software that writes your software; and unified future-proof platform for businesses with robust capabilities to automate industry-specific business processes. In addition, the company offers Pega Cloud that provides production, development, and testing services to accelerate the development and deployment of Pega applications and the Pega Platform, as well as guidance and implementation, technical support, and instructor-led and online training services. Pegasystems Inc. has a strategic alliance with KPMG LLP that assists government agencies for digital transformation. It primarily markets its software and services to financial services, healthcare, manufacturing and high tech, communications and media, insurance, government, consumer services, life sciences, and others through a direct sales force, as well as partnerships with technology providers and application developers. Pegasystems Inc. was founded in 1983 and is headquartered in Cambridge, Massachusetts.
#3 - RingCentral (NYSE:RNG)
Trailing Twelve Months EPS: ($0.35)
2018 EPS Estimate: ($0.09)
2019 EPS Estimate: ($0.30)
Stock Price: $82.47
P/E Ratio: -235.6
Consensus Rating: Buy
Ratings Breakdown: 12 Buy Ratings, 2 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $90.1429 (9.3% Upside)
RingCentral, Inc. provides software-as-a-service solutions for business communications and collaboration primarily in the United States. The company's products include RingCentral Office, a multi-tenant, multi-location, and enterprise-grade communications and collaboration solution that enables employees to communicate through voice, text, team messaging and collaboration, and HD video and Web conferencing through smartphones, tablets, PCs, and desk phones for businesses, which require a communications solution; RingCentral Professional, an inbound call routing subscription with additional text and fax capabilities primarily for smaller businesses; and RingCentral Fax solution that offers Internet fax capabilities, which allow businesses to send and receive fax documents without the need for a fax machine. Its products also comprise RingCentral Contact Center that provides a cloud based contact center solution, which delivers omni-channel capabilities; and RingCentral Glip, a team messaging and collaboration solution that allows a range of teams to stay connected through various modes of communication through an integration with RingCentral Office. RingCentral, Inc. serves a range of industries, including financial services, healthcare, legal services, real estate, retail, technology, insurance, construction, hospitality, and state and local government, as well as others. The company sells its products through a network of direct sales representatives, as well as sales agents and channel partners. RingCentral, Inc. was founded in 1999 and is headquartered in Belmont, California.
#4 - Caesars Entertainment (NASDAQ:CZR)
Trailing Twelve Months EPS: ($3.37)
2018 EPS Estimate: $0.06
2019 EPS Estimate: ($0.09)
Stock Price: $7.45
P/E Ratio: -2.2
Consensus Rating: Buy
Ratings Breakdown: 7 Buy Ratings, 3 Hold Ratings, 1 Sell Ratings.
Consensus Price Target: $13.00 (74.5% Upside)
Caesars Entertainment Corporation, through its subsidiaries, provides casino-entertainment and hospitality services in the United States and internationally. The company operates 36,000 slot machines and 2,700 table games, as well as other games comprising keno, poker, and race and sports books; and buffets, restaurants, bars, nightclubs, and lounges located throughout its casinos, as well as banquets and room service. As of March 7, 2018, it owned and operated 47 casinos. It also provides various retail and entertainment offerings in its casinos, as well as The LINQ promenade, an open-air dining, entertainment, and retail development; and operates various entertainment venues, including the Colosseum at Caesars Palace and Zappos Theater at Planet Hollywood. In addition, the company operates online gaming business that provides real money games; and owns the World Series of Poker tournaments and brand. The company was formerly known as Harrah's Entertainment Inc. and changed its name to Caesars Entertainment Corporation in November 2010. Caesars Entertainment Corporation was founded in 1937 and is based in Las Vegas, Nevada.
#5 - Iridium Communications (NASDAQ:IRDM)
Trailing Twelve Months EPS: $0.70
2018 EPS Estimate: ($0.20)
2019 EPS Estimate: ($0.55)
Stock Price: $20.10
P/E Ratio: 28.7
Consensus Rating: Buy
Ratings Breakdown: 3 Buy Ratings, 1 Hold Ratings, 1 Sell Ratings.
Consensus Price Target: $21.4375 (6.7% Upside)
Iridium Communications, Inc. is a mobile voice and data satellite communications network. Its satellite network provides communication where terrestrial wireless or wireline networks do not exist or are limited. The company's current principal lines of business include Land Mobile, Maritime, Aviation, and Government. The Land Mobile business engages in the provision of mobile satellite communications services to the land mobile sector, providing handset services to areas not served or inconsistently served by existing terrestrial communications networks. The Maritime business provides broadband terminals, embedded devices and handsets. Its market space includes merchant shipping, fishing, research vessels and specialized water craft. The Aviation business provides mobile satellite communications services to the aviation sector. Its services are used in commercial and global government aviation applications, principally by corporate jets, corporate and government helicopter fleets, specialized general aviation fleets, such as medevac companies and fire suppression fleets, and high-end personal aircraft. The Government business line involves in the provision of mobile satellite communications services to the U.S. government, principally the Department of Defense. Its voice products are used for a variety of primary and backup communications solutions, including tactical operations, logistical, administrative, morale and welfare, and emergency communications. The company's commercial services includes: Postpaid Mobile Voice and Data Satellite Communications; Prepaid Mobile Voice Satellite Communications; Iridium PTT; Broadband Data; and Machine-to-Machine services. Iridium Communications was founded on November 2, 2007 and is headquartered in McLean, VA.
#6 - Roku (NASDAQ:ROKU)
Trailing Twelve Months EPS: ($2.24)
2018 EPS Estimate: ($0.13)
2019 EPS Estimate: ($0.18)
Stock Price: $33.42
P/E Ratio: -14.9
Consensus Rating: Buy
Ratings Breakdown: 10 Buy Ratings, 3 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $63.0333 (88.6% Upside)
Roku, Inc. operates a TV streaming platform. The company operates in two segments, Player and Platform. Its platform allows users to search, discover, and access approximately 500,000 movies and TV episodes, as well as live sports, music, news, and others. As of December 31, 2017, the company had 19.3 million active accounts. It also provides advertising products, including videos ads, interactive video ads, audience development promotions, and brand sponsorships; and manufactures, sells, and licenses TVs under the Roku TV name. In addition, the company offers streaming media players and accessories under the Roku brand that allow users to access its TV streaming platform; and sells branded channel buttons on remote controls. It provides its products and services through retailers and distributors, as well as directly to customers through its Website in the United States, Canada, the United Kingdom, France, the Republic of Ireland, and various Latin American countries. The company was founded in 2002 and is headquartered in Los Gatos, California.
#7 - Liberty Media Formula One Series C (NASDAQ:FWONK)
Trailing Twelve Months EPS: $1.21
2018 EPS Estimate: ($0.26)
2019 EPS Estimate: ($0.57)
Stock Price: $31.34
P/E Ratio: 25.9
Consensus Rating: Hold
Ratings Breakdown: 1 Buy Ratings, 2 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $37.00 (18.1% Upside)
Formula One Group, through its subsidiaries, engages in the media and entertainment businesses in North America. Formula One Group was formerly known as The Liberty Media Group. The company is based in Englewood, Colorado. Formula One Group is a former subsidiary of Liberty Media Corporation.
#8 - Cornerstone OnDemand (NASDAQ:CSOD)
Trailing Twelve Months EPS: ($0.70)
2018 EPS Estimate: ($0.20)
2019 EPS Estimate: ($0.29)
Stock Price: $52.51
P/E Ratio: -75.0
Consensus Rating: Buy
Ratings Breakdown: 7 Buy Ratings, 3 Hold Ratings, 1 Sell Ratings.
Consensus Price Target: $56.80 (8.2% Upside)
Cornerstone OnDemand, Inc., together with its subsidiaries, provides learning and human capital management software through software-as-a-service model worldwide. Its enterprise human capital management platform comprises four product suites, such as Recruiting Suite that helps organizations to source and attract candidates, assess and select applicants, onboard new hires, and manage the entire recruiting process; Learning Suite, which enables clients to manage training and development programs, knowledge sharing and collaboration among employees, track compliance requirements, and support career development for employees; Performance Suite that provides tools to manage goal setting, performance reviews, competency assessments, development plans, continuous feedback, compensation management, and succession planning; and HR Administration Suite, which supports employee records administration, organizational management, employee and manager self-service, workforce planning, and compliance reporting. The company also offers PiiQ, a cloud-based talent management solution for organizations with 500 or fewer employees; and Cornerstone Edge solutions that allow clients and partners to integrate with marketplace of service providers. In addition, it provides professional services, including application configuration, system integration, business process re-engineering, change management, and training. The company serves automotive, business services, education and publishing, financial services, food and restaurants, healthcare, insurance, media and communications, non-profits, pharmaceuticals, public sector, retail, technology, and travel industries. Cornerstone OnDemand, Inc. was founded in 1999 and is headquartered in Santa Monica, California.
#9 - Zillow Group (NASDAQ:ZG)
Trailing Twelve Months EPS: $0.15
2018 EPS Estimate: ($0.27)
2019 EPS Estimate: ($0.44)
Stock Price: $31.97
P/E Ratio: 213.1
Consensus Rating: Hold
Ratings Breakdown: 7 Buy Ratings, 11 Hold Ratings, 1 Sell Ratings.
Consensus Price Target: $44.5625 (39.4% Upside)
Zillow Group, Inc. operates real estate and home-related information marketplaces on mobile and the Web in the United States. The company offers a portfolio of brands and products to enable consumers find information about homes and connect with local professionals. Its brands focus on various stages of the home lifecycle, including renting, buying, selling, and financing. The company's portfolio of consumer brands comprise real estate and rental marketplaces, such as Zillow, Trulia, StreetEasy, HotPads, Naked Apartments, RealEstate.com, and OutEast.com. It also provides a suite of marketing software and technology solutions; and owns and operates various business brands for real estate, rental, and mortgage professionals comprising Mortech, dotloop, Bridge Interactive, and New Home Feed. In addition, the company offers advertising services. Zillow Group, Inc. was incorporated in 2004 and is headquartered in Seattle, Washington.
#10 - Arrowhead Pharmaceuticals (NASDAQ:ARWR)
Trailing Twelve Months EPS: ($0.65)
2018 EPS Estimate: $0.31
2019 EPS Estimate: ($0.41)
Stock Price: $14.32
P/E Ratio: -22.0
Consensus Rating: Buy
Ratings Breakdown: 6 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $21.4467 (49.8% Upside)
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. Its medicines include ARO-HBV, a Phase I/II subcutaneous ribonucleic acid interference(RNAi) therapy candidate that is used for the treatment of chronic hepatitis B viral infection; ARO-AAT for the treatment of liver disease associated with alpha-1 antitrypsin deficiency; ARO-APOC3 and ARO-ANG3 to treat hypertriglyceridemia; ARO-Lung1 for the treatment of an undisclosed pulmonary target; ARO-HIF2 to treat renal cell carcinoma; ARO-F12 for hereditary angioedema and thromboembolic disorders; and ARO-AMG1 for the treatment of an undisclosed genetically validated cardiovascular target. Arrowhead Pharmaceuticals, Inc. has collaboration and license agreement with Amgen, Inc.; and Janssen Pharmaceuticals, Inc. to develop RNAi therapeutics. The company was formerly known as Arrowhead Research Corporation and changed its name to Arrowhead Pharmaceuticals, Inc. in April 2016. Arrowhead Pharmaceuticals, Inc. was incorporated in 1989 and is headquartered in Pasadena, California.
#11 - Alteryx (NYSE:AYX)
Trailing Twelve Months EPS: ($0.31)
2018 EPS Estimate: ($0.30)
2019 EPS Estimate: ($0.33)
Stock Price: $64.42
P/E Ratio: -207.8
Consensus Rating: Buy
Ratings Breakdown: 10 Buy Ratings, 2 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $67.0909 (4.1% Upside)
Alteryx, Inc. operates a self-service data analytics software platform that enables organizations to enhance business outcomes and the productivity of their business analysts. Its software platform includes Alteryx Designer for data preparation, blending, and analytics that could be deployable in the cloud and on premise; Alteryx Server, a secure and scalable server-based product for scheduling, sharing, and running analytic processes and applications in a Web-based environment; Alteryx Connect, a collaborative data exploration platform for discovering information assets and sharing recommendations across the enterprise; Alteryx Promote, an analytics model management product for data scientists and analytics teams to build, manage, monitor, and deploy predictive models to production; and Alteryx Analytics Gallery, a cloud-based collaboration offering that allows users to share workflows in a centralized repository. The company also provides technical support, instruction, and customer services. Alteryx, Inc. was founded in 1997 and is headquartered in Irvine, California.
#12 - TerraForm Power (NASDAQ:TERP)
Trailing Twelve Months EPS: ($1.21)
2018 EPS Estimate: $0.20
2019 EPS Estimate: ($0.13)
Stock Price: $11.50
P/E Ratio: -9.5
Dividend Yield: 6.63 %
Consensus Rating: Buy
Ratings Breakdown: 4 Buy Ratings, 3 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $12.4167 (8.0% Upside)
TerraForm Power, Inc., together with its subsidiaries, owns and operates clean power generation assets. As of December 31, 2017, its portfolio consisted of solar and wind projects located in the United States, Canada, the United Kingdom, and Chile with a combined nameplate capacity of 2,606.4 megawatts. The company was formerly known as SunEdison Yieldco, Inc. and changed its name to TerraForm Power, Inc. in May 2014. TerraForm Power, Inc. was founded in 2014 and is headquartered in New York, New York.
#13 - Redfin (NASDAQ:RDFN)
Trailing Twelve Months EPS: ($0.20)
2018 EPS Estimate: ($0.54)
2019 EPS Estimate: ($0.82)
Stock Price: $15.91
P/E Ratio: -79.6
Consensus Rating: Hold
Ratings Breakdown: 4 Buy Ratings, 6 Hold Ratings, 1 Sell Ratings.
Consensus Price Target: $22.50 (41.4% Upside)
Redfin Corporation operates as a real estate brokerage company in the United States. The company operates an online real estate marketplace and provides real estate services, such as assisting individuals to purchase or sell their residential property. It also provides title and settlement services; originates and sells mortgages; and buys and sells residential properties. The company was formerly known as Appliance Computing Inc. and changed its name to Redfin Corporation in May 2006. Redfin Corporation was incorporated in 2002 and is headquartered in Seattle, Washington.
#14 - Q2 (NYSE:QTWO)
Trailing Twelve Months EPS: ($0.48)
2018 EPS Estimate: ($0.50)
2019 EPS Estimate: ($0.61)
Stock Price: $49.17
P/E Ratio: -102.4
Consensus Rating: Buy
Ratings Breakdown: 7 Buy Ratings, 7 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $61.4554 (25.0% Upside)
Q2 Holdings, Inc. provides cloud-based digital banking solutions to regional and community financial institutions (RCFIs) in the United States. It offers Q2online, a browser-based digital banking solution that delivers RCFI-branded digital banking capabilities; Q2 Sentinel, a security analytics solution; Q2 Corporate to support RCFIs to attract and retain larger commercial accounts; and Q2 SMART, a targeting and messaging platform. The company also provides Q2 Account Opening solution; Q2 Active/Active that operates various data centers; and Q2 Patrol, an event-driven validation product. In addition, it offers Q2mobility App, a mobile and tablet digital banking solution; Q2mobile Remote Deposit Capture, a partnered solution that allows remote check deposit capture; Q2 Person-to-Person Payments, a partnered secure and integrated person-to-person payments solution; Detection Monitoring Service, a security threat tracking solution; and Q2 CardSwap that allows account holders receiving newly issued cards to automatically change their payment information with existing subscription and digital point-of-sale services. Further, the company provides Q2text, a mobile solution, which enables digital banking activities through the text messaging function of the device; Q2voice, a voice-based solution for telephones; and Q2themes, a personalization solution for customizing digital banking services. Additionally, it offers Q2clarity, an analytics solution for Q2online customers; Centrix Dispute Tracking System, an electronic transaction dispute management solution; Centrix Payments I.Q. System, an ACH file monitoring and risk reporting solution; and Centrix Exact/Transaction Management System, a fraud prevention tool. The company was formerly known as CBG Holdings, Inc. and changed its name to Q2 Holdings, Inc. in March 2013. Q2 Holdings, Inc. was founded in 2005 and is headquartered in Austin, Texas.
#15 - Spark Therapeutics (NASDAQ:ONCE)
Trailing Twelve Months EPS: ($7.63)
2018 EPS Estimate: ($1.37)
2019 EPS Estimate: ($4.41)
Stock Price: $40.09
P/E Ratio: -5.3
Consensus Rating: Buy
Ratings Breakdown: 12 Buy Ratings, 8 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $67.00 (67.1% Upside)
Spark Therapeutics, Inc. focuses on the development of gene therapy products for patients suffering from debilitating genetic diseases. Its products include LUXTURNA (voretigene neparvovec), which is in Phase III clinical trial for the treatment of genetic blinding conditions caused by mutations in the RPE65 gene; and SPK-CHM that is in Phase I/II clinical trial for the treatment of choroideremia. The company's products also comprise SPK-7001 that is in Phase 1/2 trial for choroideremia; SPK-9001, which is in Phase 1/2 trial for hemophilia B; and SPK-8011 that is in Phase 1/2 trial hemophilia A. In addition, its product candidates and development programs include SPK-FVIII program to treat hemophilia A; SPK-TPP1 program for the treatment of CLN2 disease; RhoNova for the treatment of rhodopsin-linked autosomal dominant retinitis pigmentosa; and other neurodegenerative diseases. The company has collaboration agreement with Pfizer, Inc. for the development and commercialization of SPK-FIX product candidates in its gene therapy program for the treatment of hemophilia B. Spark Therapeutics, Inc. was founded in 2013 and is headquartered in Philadelphia, Pennsylvania.
#16 - 2U (NASDAQ:TWOU)
Trailing Twelve Months EPS: ($0.54)
2018 EPS Estimate: ($0.67)
2019 EPS Estimate: ($1.03)
Stock Price: $55.39
P/E Ratio: -102.6
Consensus Rating: Buy
Ratings Breakdown: 9 Buy Ratings, 2 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $83.0909 (50.0% Upside)
2U, Inc. operates as an education technology company in the United States, Hong Kong, South Africa, and the United Kingdom. The company operates through two segments, Graduate Program Segment and Short Course Segment. It offers front-end technology and services, including online learning platform, student and faculty and immersion support, accessibility, admissions application advising, in-program student field placements, and faculty recruiting. The company provides back-end technology and services comprising graduate program launch and operations applications, university systems integration applications, content management system, admission application processing portal, customer relationship management, content development, student acquisition, and state authorization services. The company was formerly known as 2Tor Inc. and changed its name to 2U, Inc. in October 2012. 2U, Inc. was founded in 2008 and is headquartered in Lanham, Maryland.
#17 - HUTCHISON CHINA/S (NASDAQ:HCM)
Trailing Twelve Months EPS: ($0.22)
2018 EPS Estimate: ($0.58)
2019 EPS Estimate: ($0.72)
Stock Price: $33.89
P/E Ratio: -154.0
Consensus Rating: N/A
Ratings Breakdown: 0 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: N/A
Hutchison China MediTech Limited, a biopharmaceutical company, engages in the research, development, manufacture, and sale of pharmaceuticals and healthcare products primarily in the People's Republic of China and Hong Kong. It operates through Innovation Platform and Commercial Platform segments. The company discovers and develops therapeutics in oncology and autoimmune diseases, as well as provides research and development services; and develops, manufactures, distributes, markets, and sells prescription and over-the-counter pharmaceutical products, and consumer health products under the Baiyunshan and Shang Yao brands. Its clinical drug candidates include Savolitinib, an inhibitor for treating non-small cell lung, colorectal, and gastric cancer, as well as papillary renal cell carcinoma; Fruquintinib, an oral inhibitor for the treatment of colorectal, non-small cell lung, and gastric cancer; Sulfatinib for treating neuroendocrine tumors, and thyroid and biliary tract cancer; and Epitinib for the treatment of non-small cell lung cancer, as well as for patients with glioblastoma. The company also develops Theliatinib epidermal growth factor receptor inhibitor for treating solid tumors, as well as for patients with esophageal cancer; HMPL-523, an oral inhibitor for the treatment of immunology, rheumatoid arthritis, and hematological cancers; HMPL-689, a small molecule inhibitor for the treatment of hematologic cancers, autoimmunity and transplant organ rejection, and other related inflammation diseases; HMPL-453, a small molecule inhibitor for the treatment of solid tumors; and HMPL-004 for the treatment of ulcerative colitis and Crohn's disease. It has strategic alliances with AstraZeneca AB (publ); Eli Lilly and Company; and Nestlé Health Science SA. The company was founded in 2000 and is headquartered in Central, Hong Kong. Hutchison China MediTech Limited is a subsidiary of Hutchison Healthcare Holdings Limited.
#18 - Halozyme Therapeutics (NASDAQ:HALO)
Trailing Twelve Months EPS: $0.45
2018 EPS Estimate: ($0.56)
2019 EPS Estimate: ($0.64)
Stock Price: $15.17
P/E Ratio: 33.7
Consensus Rating: Hold
Ratings Breakdown: 4 Buy Ratings, 3 Hold Ratings, 1 Sell Ratings.
Consensus Price Target: $21.00 (38.4% Upside)
Halozyme Therapeutics, Inc., a biotechnology company, researches, develops, and commercializes human enzymes and other drug candidates in the United States, Switzerland, and internationally. The company's human enzymes are used to facilitate the delivery of injected drugs and fluids, enhancing the efficacy and the convenience of other drugs or can be used to alter tissue structures for clinical benefit. Its products are based on the Enhanze technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. The company's pipeline include Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous fluid administration for achieving hydration; to enhance the dispersion and absorption of other injected drugs; in subcutaneous urography; and to enhance resorption of radiopaque agents. It also develops PEGylated recombinant human hyaluronidase for the treatment of pancreatic ductal adenocarcinoma, non-small cell lung cancer, gastric cancer, metastatic breast cancer, and cholangiocarcinoma and gall bladder cancer. In addition, the company develops PEGylated adenosine deaminase 2, an immune checkpoint inhibitor that targets adenosine. It has collaborations with F. Hoffmann-La Roche, Ltd.; Hoffmann-La Roche, Inc.; Baxalta US Inc.; Baxalta GmbH; Pfizer Inc.; Janssen Biotech, Inc.; AbbVie, Inc.; Eli Lilly and Company; Bristol-Myers Squibb Company; and Alexion Pharma Holding. Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California.
#19 - Smartsheet (NYSE:SMAR)
2018 EPS Estimate: ($0.60)
2019 EPS Estimate: ($0.73)
Stock Price: $24.77
Consensus Rating: Buy
Ratings Breakdown: 7 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $35.1667 (42.0% Upside)
Smartsheet Inc. provides cloud-based platform for execution of work. It enables teams and organizations to plan, capture, manage, automate, and report on work. The company offers Smartdashboards that provides the status of work to align individuals, managers, and executives; Smartportals to easily locate and access from any device the resources available for a project without IT assistance; Smartcards to organize, share, and act on workflows; and Smartgrids to keep teams on task by easily tracking multiple moving parts. It also provides Smartprojects; Smartcalendars, which align teams and organizations by connecting deadlines to workflows; Smartforms enables business users to collect information in a structured and consistent format; Smartautomation that automates repetitive processes; and Smartintegrations enable organizations and teams to connect, sync, and extend enterprise applications. In addition, it offers Connectors; and Control Center that enables organizations to achieve consistent work execution. As of January 31, 2018, it served approximately 92,000 customers. The company was founded in 2005 and is headquartered in Bellevue, Washington.
#20 - Sangamo Therapeutics (NASDAQ:SGMO)
Trailing Twelve Months EPS: ($0.70)
2018 EPS Estimate: ($0.72)
2019 EPS Estimate: ($0.99)
Stock Price: $11.48
P/E Ratio: -16.4
Consensus Rating: Buy
Ratings Breakdown: 5 Buy Ratings, 3 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $19.8333 (72.8% Upside)
Sangamo Therapeutics, Inc. focuses on translating science into genomic therapies that transform patients' lives using platform technologies in genome editing, gene therapy, gene regulation, and cell therapy. The company's zinc finger DNA-binding protein (ZFP) technology enables specific genome editing and gene regulation. The ZFPs could be engineered to make ZFP nucleases (ZFNs), proteins that could be used to modify DNA sequences by adding or knocking out specific genes; and ZFP transcription factors (ZFP TFs), proteins that can be used to turn genes on or off. Its therapeutic products include SB-728-T, a ZFN-mediated autologous T-cell product for human immunodeficiency virus and acquired immunodeficiency syndrome (HIV/AIDS), which is in Phase II and I clinical trials; and SB-728-HSPC that is in Phase I/II clinical trials for HIV/AIDS. The company also engages in Phase I/II studies of in vivo genome editing applications of ZFP Therapeutics for Hemophilia B, Hemophilia A, and Mucopolysaccharidosis I (MPS) and MPS II, which are lysosomal storage disorder (LSD); preclinical programs in other LSDs; and research stage programs in central nervous system disorders and cancer immunotherapies. It has collaborative partnerships with Biogen Inc. to develop therapeutic genome editing products in hemoglobinopathies; and Shire International GmbH to develop preclinical development program in Huntington's disease, as well as license agreements with Sigma-Aldrich Corporation to develop laboratory research reagents and Dow AgroSciences, LLC to modify the protein expression of plant cells and plants. The company also has a research collaboration and license agreement with Pfizer Inc; and collaboration with Kite for developing ex vivo cell therapies in oncology. The company was formerly known as Sangamo BioSciences, Inc. and changed its name to Sangamo Therapeutics, Inc. in January 2017. Sangamo Therapeutics, Inc. was founded in 1995 and is headquartered in Richmond, California.
